These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18405845)

  • 21. Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.
    Kochan LD; Qureshi AI; Fallon BA
    Curr Psychiatry Rep; 2000 Aug; 2(4):327-34. PubMed ID: 11122977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obsessive compulsive disorder: serotonin and beyond.
    Zohar J; Chopra M; Sasson Y; Amiaz R; Amital D
    World J Biol Psychiatry; 2000 Apr; 1(2):92-100. PubMed ID: 12607204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological guidelines for the treatment of refractory patients with obsessive-compulsive disorder].
    Toro-Martínez E
    Vertex; 2005; 16(64):442-5. PubMed ID: 16314898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy for obsessive-compulsive disorder.
    Hollander E; Kaplan A; Allen A; Cartwright C
    Psychiatr Clin North Am; 2000 Sep; 23(3):643-56. PubMed ID: 10986733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin dysfunction disorders: a behavioral neurochemistry perspective.
    Petty F; Davis LL; Kabel D; Kramer GL
    J Clin Psychiatry; 1996; 57 Suppl 8():11-6. PubMed ID: 8698675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A selective serotonin reuptake inhibitor ameliorates obsessive-compulsive disorder-like perseverative behavior by attenuating 5-HT
    Hatakama H; Asaoka N; Nagayasu K; Shirakawa H; Kaneko S
    Neuropharmacology; 2022 Mar; 206():108926. PubMed ID: 34921828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    J Clin Psychiatry; 1994 Mar; 55 Suppl():24-31. PubMed ID: 7521326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurobiology and clinical pharmacology of obsessive-compulsive disorder.
    Micallef J; Blin O
    Clin Neuropharmacol; 2001; 24(4):191-207. PubMed ID: 11479390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
    Oulis P; Mourikis I; Konstantakopoulos G
    Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?
    Ersche KD; Cumming P; Craig KJ; Müller U; Fineberg NA; Bullmore ET; Robbins TW
    J Psychopharmacol; 2012 Jun; 26(6):887-90. PubMed ID: 21746752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.